Related Experiment Videos
Preliminary experience of infusional brachytherapy using colloidal 32P
S E Order1, J A Siegel, R Principato
1Department of Radiological Physics, Cooper Hospital/University Medical Center, Camden, New Jersey 08103, USA.
Annals of the Academy of Medicine, Singapore
|May 1, 1996
Summary
This study introduces a novel interstitial infusion technique for targeted cancer therapy, achieving 75-100% tumor dose deposition. This method shows promise for high-dose delivery without toxicity in various solid tumors.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Previous attempts using radiolabeled antibodies for Hodgkin's disease and hepatocellular cancer were limited by poor tumor dose deposition.
- Factors such as increased tumor pressure, reduced vascularity, and poor diffusion hindered effective delivery of radiolabeled antibodies to tumors.
Purpose of the Study:
- To review a novel interstitial tumor infusion technique for enhanced radiopharmaceutical delivery.
- To evaluate the efficacy and safety of this technique in achieving high tumor dose deposition and controlling solid tumors.
Main Methods:
- Intratumoral infusion of macroaggregated albumin to block tumor vasculature.
- Interstitial tumor infusion of colloidal chromic 32Phosphorus under computed tomographic guidance.
- Phase I clinical studies in various solid tumors, including non-resectable pancreatic cancer.
Main Results:
- Achieved 75% to 100% tumor dose deposition via interstitial infusion.
- Demonstrated the potential for extremely high radiation doses (900,000 cGy to 1.7 million cGy) without observed toxicity.
- Observed tumor control and remission in treated patients.
Conclusions:
- The described interstitial infusion technique significantly improves radiopharmaceutical tumor dose deposition.
- This method allows for safe and effective delivery of high radiation doses, leading to tumor control and remission.
- The technique shows potential for treating various solid tumors, including challenging cases like non-resectable pancreatic cancer.